Ligand Pharmaceuticals (LGNYZ) Other Gross PP&E Adjustments (2016 - 2025)
Historic Other Gross PP&E Adjustments for Ligand Pharmaceuticals (LGNYZ) over the last 15 years, with Q3 2025 value amounting to -$7.6 million.
- Ligand Pharmaceuticals' Other Gross PP&E Adjustments fell 631.55% to -$7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.6 million, marking a year-over-year decrease of 631.55%. This contributed to the annual value of $8.9 million for FY2024, which is 3575.26% down from last year.
- Per Ligand Pharmaceuticals' latest filing, its Other Gross PP&E Adjustments stood at -$7.6 million for Q3 2025, which was down 631.55% from -$8.0 million recorded in Q2 2025.
- Over the past 5 years, Ligand Pharmaceuticals' Other Gross PP&E Adjustments peaked at $17.9 million during Q4 2022, and registered a low of -$32.1 million during Q3 2022.
- For the 5-year period, Ligand Pharmaceuticals' Other Gross PP&E Adjustments averaged around -$7.3 million, with its median value being -$7.6 million (2025).
- Examining YoY changes over the last 5 years, Ligand Pharmaceuticals' Other Gross PP&E Adjustments showed a top increase of 29379.26% in 2021 and a maximum decrease of 29341.77% in 2021.
- Quarter analysis of 5 years shows Ligand Pharmaceuticals' Other Gross PP&E Adjustments stood at $11.0 million in 2021, then surged by 63.51% to $17.9 million in 2022, then dropped by 23.06% to $13.8 million in 2023, then plummeted by 35.75% to $8.9 million in 2024, then tumbled by 185.78% to -$7.6 million in 2025.
- Its Other Gross PP&E Adjustments was -$7.6 million in Q3 2025, compared to -$8.0 million in Q2 2025 and -$800000.0 in Q1 2025.